Talaris Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.67
- Today's High:
- $2.851
- Open Price:
- $2.82
- 52W Low:
- $0.89
- 52W High:
- $4.144
- Prev. Close:
- $2.82
- Volume:
- 121477
Company Statistics
- Market Cap.:
- $128.67 million
- Book Value:
- 3.488
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -22.81%
- Return on Equity TTM:
- -41.64%
Company Profile
Talaris Therapeutics Inc had its IPO on 2021-05-07 under the ticker symbol TALS.
The company operates in the Healthcare sector and Biotechnology industry. Talaris Therapeutics Inc has a staff strength of 84 employees.
Stock update
Shares of Talaris Therapeutics Inc opened at $2.82 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.67 - $2.85, and closed at $2.68.
This is a -4.96% slip from the previous day's closing price.
A total volume of 121,477 shares were traded at the close of the day’s session.
In the last one week, shares of Talaris Therapeutics Inc have slipped by -8.53%.
Talaris Therapeutics Inc's Key Ratios
Talaris Therapeutics Inc has a market cap of $128.67 million, indicating a price to book ratio of 0.2762 and a price to sales ratio of 0.
In the last 12-months Talaris Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-68159000. The EBITDA ratio measures Talaris Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Talaris Therapeutics Inc’s operating margin was 0% while its return on assets stood at -22.81% with a return of equity of -41.64%.
In Q2, Talaris Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Talaris Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Talaris Therapeutics Inc’s profitability.
Talaris Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.9822. Its price to sales ratio in the trailing 12-months stood at 0.
Talaris Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $159.12 million
- Total Liabilities
- $10.13 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $221000
- Dividend Payout Ratio
- 0%
Talaris Therapeutics Inc ended 2024 with $159.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $159.12 million while shareholder equity stood at $148.43 million.
Talaris Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.13 million in other current liabilities, 4000.00 in common stock, $-201976000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.35 million and cash and short-term investments were $152.25 million. The company’s total short-term debt was $601,000 while long-term debt stood at $0.
Talaris Therapeutics Inc’s total current assets stands at $156.21 million while long-term investments were $0 and short-term investments were $133.90 million. Its net receivables were $0 compared to accounts payable of $2.93 million and inventory worth $0.
In 2024, Talaris Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $221000.
Comparatively, Talaris Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.68
- 52-Week High
- $4.144
- 52-Week Low
- $0.89
- Analyst Target Price
- $20
Talaris Therapeutics Inc stock is currently trading at $2.68 per share. It touched a 52-week high of $4.144 and a 52-week low of $4.144. Analysts tracking the stock have a 12-month average target price of $20.
Its 50-day moving average was $2.95 and 200-day moving average was $2.2 The short ratio stood at 1.54 indicating a short percent outstanding of 0%.
Around 1191% of the company’s stock are held by insiders while 7766.5% are held by institutions.
Frequently Asked Questions About Talaris Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.